Table 1.
Patient demographics and baseline characteristics
| Characteristics | Dulaglutide 1.5 mg N = 239 | Dulaglutide 0.75 mg N = 239 | Glimepiride N = 242 | Total N = 720 | P‐value* |
|---|---|---|---|---|---|
| Gender, n | 239 | 239 | 242 | 720 | .794 |
| Female, n (%) | 105 (43.9) | 112 (46.9) | 112 (46.3) | 329 (45.7) | |
| Male, n (%) | 134 (56.1) | 127 (53.1) | 130 (53.7) | 391 (54.3) | |
| Age, years, n | 239 | 239 | 242 | 720 | .150 |
| Mean (SD) | 52.7 (10.75) | 53.8 (10.09) | 52.0 (10.05) | 52.8 (10.32) | |
| Age group, n | 239 | 239 | 242 | 720 | .132 |
| <65 years, n (%) | 213 (89.1) | 208 (87.0) | 224 (92.6) | 645 (89.6) | |
| ≥65 years, n (%) | 26 (10.9) | 31 (13.0) | 18 (7.4) | 75 (10.4) | |
| Country/region, n | 239 | 239 | 242 | 720 | >.999 |
| China, n (%) | 184 (77.0) | 186 (77.8) | 186 (76.9) | 556 (77.2) | |
| Korea, n (%) | 26 (10.9) | 25 (10.5) | 27 (11.2) | 78 (10.8) | |
| Taiwan, n (%) | 29 (12.1) | 28 (11.7) | 29 (12.0) | 86 (11.9) | |
| BMI, kg/m2, n | 239 | 238 | 242 | 719 | .213 |
| Mean (SD) | 25.8 (3.43) | 26.2 (3.49) | 25.7 (3.14) | 25.9 (3.36) | |
| HbA1c, n | 239 | 239 | 242 | 720 | .317 |
| Mean (SD), mmol/mol | 63.6 (10.42) | 64.04 (11.27) | 62.51 (11.07) | 63.38 (10.93) | |
| Mean (SD), % | 8.0 (0.95) | 8.0 (1.03) | 7.9 (1.01) | 8.0 (1.00) | |
| HbA1c group, n | 239 | 239 | 242 | 720 | .506 |
| <69 mmol/mol (<8.5%), n (%) | 171 (71.5) | 165 (69.0) | 179 (74.0) | 515 (71.5) | |
| ≥69 mmol/mol (≥8.5%), n (%) | 68 (28.5) | 74 (31.0) | 63 (26.0) | 205 (28.5) | |
| Duration of T2D, years, n | 239 | 239 | 241 | 719 | .383 |
| Mean (SD) | 4.0 (4.44) | 3.5 (4.06) | 3.8 (4.09) | 3.7 (4.20) | |
| History of ≥1 previous OAM, n | 239 | 239 | 242 | 720 | .977 |
| Yes, n (%) | 135 (56.5) | 136 (56.9) | 139 (57.4) | 410 (56.9) | |
| No, n (%) | 104 (43.5) | 103 (43.1) | 103 (42.6) | 310 (43.1) | |
| Current alcohol use, n | 239 | 239 | 241 | 719 | .139 |
| Yes, n (%) | 56 (23.4) | 43 (18.0) | 40 (16.6) | 139 (19.3) | |
| No, n (%) | 183 (76.6) | 196 (82.0) | 201 (83.4) | 580 (80.7) | |
| Current tobacco use, n | 237 | 239 | 241 | 717 | .032 |
| Yes, n (%) | 70 (29.5) | 46 (19.2) | 60 (24.9) | 176 (24.5) | |
| No, n (%) | 167 (70.5) | 193 (80.8) | 181 (75.1) | 541 (75.5) | |
| Vital signs (sitting position), n | 239 | 239 | 242 | 720 | |
| Systolic BP, mm Hg, Mean (SD) | 128 (13.3) | 128 (13.7) | 126 (14.7) | 127 (13.9) | 0.260 |
| Diastolic BP, mm Hg, Mean (SD) | 79 (8.7) | 79 (9.3) | 78 (8.6) | 78 (8.8) | 0.312 |
| Pulse rate, bpm, Mean (SD) | 76 (9.6) | 75 (9.3) | 77 (9.7) | 76 (9.5) | 0.131 |
Abbreviations: BMI, body mass index; BP, blood pressure; bpm, beats per minute; HbA1c, glycated haemoglobin; N, total number of patients in specified treatment group; n, number of patients in specified category; OAM, oral antidiabetic medication; T2D, type 2 diabetes.
*
P‐value is from Fisher's exact test for categorical variables, and is from an analysis of variance (ANOVA) model for continuous variables.